AGP Executive Report
Last update: 2 hours agoDrug Safety: India is proposing immediate suspension of drugmakers’ licences when products fail quality tests, alongside tighter manufacturing checks. China Pharma: Boehringer Ingelheim signed a deal with Sino Biopharmaceutical covering six cancer programs, worth up to $7 billion in potential payments; China’s Hinova also licensed an autoimmune drug candidate to Evommune in a deal worth up to $1.1 billion. Nutrition & Diabetes: Danone opened its second China R&D hub, with a gut-microbiome lab and pilot production plant. Abbott and Novo Nordisk are expanding semaglutide access across Asia-Pacific. Diagnostics: Siemens Healthineers is carving out its diagnostics business as China weakness weighs on growth; separation is expected by mid-2028. Climate & Health: Heat waves were linked to 19,338 deaths in China in 2025. A study estimates that full compliance with China’s tighter PM2.5 limit could have prevented about 234,000 pollution-related deaths in 2024.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
